PARSHALL B LYNNE 4
4 · IONIS PHARMACEUTICALS INC · Filed Apr 17, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) Director Parshall B. Lynne Sells Shares
What Happened Parshall B. Lynne, a director of Ionis Pharmaceuticals (IONS), sold 4,466 shares at a weighted-average price of $76.19 (proceeds $340,265) and 534 shares at a weighted-average price of $76.97 (proceeds $41,102) on April 15, 2026. Total disposition was 5,000 shares for approximately $381,367. These were sales (not purchases) executed under a pre-established trading plan.
Key Details
- Transaction date: April 15, 2026 (reported on Form 4 filed April 17, 2026) — appears timely.
- Lot 1: 4,466 shares; reported weighted-average $76.19; actual sale prices ranged $75.77–$76.70 (per footnote).
- Lot 2: 534 shares; reported weighted-average $76.97; actual sale prices ranged $76.85–$77.115 (per footnote).
- Footnote: Sales were made pursuant to a Rule 10b5-1 trading plan adopted May 6, 2025. The filer offers to provide a breakdown of trades by price within the reported ranges upon request.
- Shares owned after the transaction: not specified in the details provided.
Context Sales executed under a Rule 10b5-1 plan are generally pre-scheduled and are often routine liquidity events rather than real-time signals about the insider’s view of the company. For retail investors, purchases by insiders tend to be more informative about insider conviction; this filing documents a planned sale totaling about $381K.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-04-15$76.19/sh−4,466$340,265→ 51,878 total - Sale
Common Stock
[F1][F3]2026-04-15$76.97/sh−534$41,102→ 51,344 total
Footnotes (3)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.77 to $76.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.85 to $77.115 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.